The role of PET imaging in Immuno-oncology
Immunotherapy has shown promising outcomes in multiple cancer types and is considered a breakthrough technology when it comes to anti-cancer therapies within cancer care strategies. Despite the prolonged clinical response achieved, response rate are low and variable. For this reason, the use of biomarkers or more effectively, in vivo imaging biomarkers, like PET probes, has a great potential to improve response evaluation in patients receiving immunotherapy.
What will you learn from the webinar ?
- ImmunoPET for imaging immune responses - 18F labeled agents - By Dr. Jelena Levi
- ImmunoPET: Engineered antibodies for imaging immune responses - By Dr. Anna Wu